Hereditary transthyretin amyloidosis

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with vutrisiran under the National Health Act 1953, section 100 for adult patients with hereditary transthyretin amyloidosis.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing vutrisiran.

Section 100 arrangements

Vutrisiran

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending either:

an approved private hospital
a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

Treatment specifics

To be eligible for initial PBS-subsidised treatment with vutrisiran, patients must be treated by, or in consultation with, a consultant with experience in the management of amyloid disorders.

Authority applications

Please note: You’ll get an immediate assessment when you request PBS authorities online.

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised vutrisiran to treat hereditary transthyretin amyloidosis can be made in:

real time using the Online PBS Authorities system
writing and using HPOS Form upload
writing and mailed to PBS Complex Drugs Programs.

All written applications must include:

details of the proposed prescription or prescriptions
the completed hereditary transthyretin amyloidosis - vutrisiran - initial authority application form
relevant attachments.

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised vutrisiran to treat hereditary transthyretin amyloidosis can be made in:

real time using the Online PBS Authorities system
writing and using HPOS Form upload
writing and mailed to PBS Complex Drugs Programs.